Live
- Workout for these many days in a week to see optimal results
- UN General Assembly to vote on granting Palestine increased status
- Top Indian sneaker brands to watch out for
- 5 fabrics to purchase when visiting Gujarat
- South Korean ministry voices regret on Japan's 'pressure' over Line messenger
- Indians buying luxury homes more than ever, affordable housing sees 20 pc dip: Report
- SC releases CM Kejriwal on interim bail till June 1
- Harsher laws insufficient to curb political violence: German Justice Minister
- Nettru murder case, NIA arrests three
- 'Will always protect reservation for SC, ST and OBC', assures PM Modi
Gilead eyes remdesivir supplies for 1 million by year end
Amid positive results from two trials of investigational antiviral drug remdesivir on hospitalised COVID-19 patients, its US-based maker Gilead Sciences has said it is ramping up production of the drug and by year end it should have enough supplies for treating over 1 million patients.
New York: Amid positive results from two trials of investigational antiviral drug remdesivir on hospitalised COVID-19 patients, its US-based maker Gilead Sciences has said it is ramping up production of the drug and by year end it should have enough supplies for treating over 1 million patients.
"We've significantly reduced lead times and expanded our global network of partners. As additional raw materials come available, we'll have an exponential increase in supplies towards the latter half of this year," Gilead Sciences CEO Daniel O'Day said during an earnings call with analysts as the company reported its Q1 2020 results on Thursday.
"We hope to have produced enough supplies to treat over a million patients by year end. We are also working to build a global consortium of pharmaceutical and chemical manufacturers to expand global capacity and production," he said.
